Advances in stem cell mobilization

Blood Reviews

Volumn 26, Issue 6, 2012, Pages 267-278

  Motabi, Ibraheem H ^a   DiPersio, John F ^a  

^a USA   (United States)

Author keywords

G CSF; Mobilization; Plerixafor; Stem cell transplantation

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 5 (4 PHENYL 5 TRIFLUOROMETHYL 2 THIENYL) 3 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 OXADIAZOLE; ANANDAMIDE; BORTEZOMIB; CALCIUM SENSING RECEPTOR; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CARMUSTINE; CD4 ANTIGEN; CERAMIDE 1 PHOSPHATE; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CYCLOPHOSPHAMIDE; ENDOCANNABINOID; FINGOLIMOD; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN; METHOTREXATE; NATALIZUMAB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARATHYROID HORMONE; PLACEBO; PLERIXAFOR; POL 6326; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SPHINGOSINE 1 PHOSPHATE; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL CRAMP; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW CELL; BONE PAIN; CAPILLARY LEAK SYNDROME; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL RENEWAL; CELL STRUCTURE; CELL TRANSPORT; CHILL; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; DIARRHEA; DIZZINESS; DRUG COST; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; EVENING DOSAGE; FATIGUE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HOMEOSTASIS; HUMAN; INJECTION SITE PAIN; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL BLOOD STEM CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; SPLEEN RUPTURE; STEM CELL MOBILIZATION; TREATMENT FAILURE;

ANIMALS; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; RECEPTORS, CXCR4;

EID: 84868208965     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2012.09.003     Document Type: Article

References (213)

1. Horowitz M.M., Gale R.P., Sondel P.M., Goldman J.M., Kersey J., Kolb H.J., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood Feb. 1 1990, 75(3):555-562.
2. Weiden P.L., Flournoy N., Sanders J.E., Sullivan K.M., Thomas E.D. Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplant Proc Mar. 1981, 13(1 Pt 1):248-251.
3. Weiden P.L., Flournoy N., Thomas E.D., et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med May 10 1979, 300(19):1068-1073.
4. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med May 8 2003, 348(19):1875-1883.
5. Dohner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood January 21 2010, 115(3):453-474.
6. Harousseau J.L., Moreau P. Role of bone marrow transplantation in the disease pathway of myeloma. J Natl Compr Canc Netw Feb. 2007, 5(2):163-169.
7. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med Dec. 7 1995, 333(23):1540-1545.
8. Villanueva M.L., Vose J.M. The role of hematopoietic stem cell transplantation in non-Hodgkin lymphoma. Clin Adv Hematol Oncol Jul. 2006, 4(7):521-530.
9. Goodman J.W., Hodgson G.S. Evidence for stem cells in the peripheral blood of mice. Blood Jun. 1962, 19:702-714.
10. Lohrmann H.P., Schreml W., Fliedner T.M., Heimpel H. Reaction of human granulopoiesis to high-dose cyclophosphamide therapy. Blut Jan. 22 1979, 38(1):9-16.
11. Richman C.M., Weiner R.S., Yankee R.A. Increase in circulating stem cells following chemotherapy in man. Blood Jun. 1976, 47(6):1031-1039.
12. Abrams R., Glaubiger D., Appelbaum F., Deisseroth A. Result of attempted hematopoietic reconstitution using isologous, peripheral blood mononuclear cells: a case report. Blood September 1 1980, 56(3):516-520.
13. Juttner C.A., To L.B., Haylock D.N., Branford A., Kimber R.J. Circulating autologous stem cells collected in very early remission from acute non-lymphoblastic leukaemia produce prompt but incomplete haemopoietic reconstitution after high dose melphalan or supralethal chemoradiotherapy. Br J Haematol 1985, 61(4):739-745.
14. Kessinger A., Armitage J.O., Landmark J.D., Weisenburger D.D. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol Mar. 1986, 14(3):192-196.
15. Krause D.S. Regulation of hematopoietic stem cell fate. Oncogene May 13 2002, 21(21):3262-3269.
16. Beckmann J., Scheitza S., Wernet P., Fischer J.C., Giebel B. Asymmetric cell division within the human hematopoietic stem and progenitor cell compartment: identification of asymmetrically segregating proteins. Blood June 15 2007, 109(12):5494-5501.
17. Ting S.B., Deneault E., Hope K., Cellot S., Chagraoui J., Mayotte N., et al. Asymmetric segregation and self-renewal of hematopoietic stem and progenitor cells with endocytic Ap2a2. Blood March 15 2012, 119(11):2510-2522.
18. Trumpp A., Essers M., Wilson A. Awakening dormant haematopoietic stem cells. Nat Rev Immunol Mar. 2010, 10(3):201-209.
19. Gong J.K. Endosteal marrow: a rich source of hematopoietic stem cells. Science 1978, 199(4336):1443-1445.
20. Grassinger J., Haylock D.N., Williams B., Olsen G.H., Nilsson S.K. Phenotypically identical hemopoietic stem cells isolated from different regions of bone marrow have different biologic potential. Blood Oct. 28 2010, 116(17):3185-3196.
21. Lo Celso C., Fleming H.E., Wu J.W., Zhao C.X., Miake-Lye S., Fujisaki J., et al. Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. Nature Jan. 1 2009, 457(7225):92-96.
22. Lord B.I., Testa N.G., Hendry J.H. The relative spatial distributions of CFUs and CFUc in the normal mouse femur. Blood Jul. 1975, 46(1):65-72.
23. Nilsson S.K., Johnston H.M., Coverdale J.A. Spatial localization of transplanted hemopoietic stem cells: inferences for the localization of stem cell niches. Blood Apr. 15 2001, 97(8):2293-2299.
24. Xie Y., Yin T., Wiegraebe W., He X.C., Miller D., Stark D., et al. Detection of functional haematopoietic stem cell niche using real-time imaging. Nature Jan. 1 2009, 457(7225):97-101.
25. Ehninger A., Trumpp A. The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. J Exp Med March 14 2011, 208(3):421-428.
26. Lymperi S., Ferraro F., Scadden D.T. The HSC niche concept has turned 31. Ann N Y Acad Sci 2010, 1192(1):12-18.
27. Calvi L.M., Adams G.B., Weibrecht K.W., Weber J.M., Olson D.P., Knight M.C., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature Oct. 23 2003, 425(6960):841-846.
28. Visnjic D., Kalajzic Z., Rowe D.W., Katavic V., Lorenzo J., Aguila H.L. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood May 1 2004, 103(9):3258-3264.
29. Mendez-Ferrer S., Michurina T.V., Ferraro F., Mazloom A.R., MacArthur B.D., Lira S.A., et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature Aug. 12 2010, 466(7308):829-834.
30. Omatsu Y., Sugiyama T., Kohara H., Kondoh G., Fujii N., Kohno K., et al. The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. Immunity Sep. 24 2010, 33(3):387-399.
31. Sugiyama T., Kohara H., Noda M., Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity Dec. 2006, 25(6):977-988.
32. Katayama Y., Battista M., Kao W.-M., Hidalgo As., Peired A.J., Thomas S.A., et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 2006, 124(2):407-421.
33. Mendez-Ferrer S., Lucas D., Battista M., Frenette P.S. Haematopoietic stem cell release is regulated by circadian oscillations. Nature 2008, 452(7186):442-447.
34. Mendez-Ferrer S., Michurina T.V., Ferraro F., Mazloom A.R., MacArthur B.D., Lira S.A., et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010, 466(7308):829-834.
35. Yamazaki K., Allen T.D. Ultrastructural morphometric study of efferent nerve terminals on murine bone marrow stromal cells, and the recognition of a novel anatomical unit: the "neuro-reticular complex". Am J Anat 1990, 187(3):261-276.
36. Chow A., Lucas D., Hidalgo A., Mendez-Ferrer S., Hashimoto D., Scheiermann C., et al. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J Exp Med Feb. 14 2011, 208(2):261-271.
37. Christopher M.J., Rao M., Liu F., Woloszynek J.R., Link D.C. Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in mice. J Exp Med Feb. 14 2011, 208(2):251-260.
38. Winkler I.G., Sims N.A., Pettit A.R., Barbier V., Nowlan B., Helwani F., et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood Dec. 2 2010, 116(23):4815-4828.
39. Christopher M.J., Rao M., Liu F., Woloszynek J.R., Link D.C. Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in mice. J Exp Med February 14 2011, 208(2):251-260.
40. Assmus B., Iwasaki M., Schachinger V., Roexe T., Koyanagi M., Iekushi K., et al. Acute myocardial infarction activates progenitor cells and increases Wnt signalling in the bone marrow. Eur Heart J Dec. 15 2011, 33(15):1911-1919.
41. Baldridge M.T., King K.Y., Goodell M.A. Inflammatory signals regulate hematopoietic stem cells. Trends Immunol Feb. 2011, 32(2):57-65.
42. Cheshier S.H., Prohaska S.S., Weissman I.L. The effect of bleeding on hematopoietic stem cell cycling and self-renewal. Stem Cells Dev Oct. 2007, 16(5):707-717.
43. Leone A.M., Rutella S., Bonanno G., Abbate A., Rebuzzi A.G., Giovannini S., et al. Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Eur Heart J Jun. 2005, 26(12):1196-1204.
44. Arai F., Hirao A., Ohmura M., Sato H., Matsuoka S., Takubo K., et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell Jul. 23 2004, 118(2):149-161.
45. Thoren L.A., Liuba K., Bryder D., Nygren J.M., Jensen C.T., Qian H., et al. Kit regulates maintenance of quiescent hematopoietic stem cells. J Immunol Feb. 15 2008, 180(4):2045-2053.
46. Yoshihara H., Arai F., Hosokawa K., Hagiwara T., Takubo K., Nakamura Y., et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell Dec. 13 2007, 1(6):685-697.
47. Hattori K., Heissig B., Tashiro K., Honjo T., Tateno M., Shieh J.H., et al. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood Jun. 1 2001, 97(11):3354-3360.
48. Kollet O., Dar A., Shivtiel S., Kalinkovich A., Lapid K., Sztainberg Y., et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med Jun. 2006, 12(6):657-664.
49. Sweeney E.A., Lortat-Jacob H., Priestley G.V., Nakamoto B., Papayannopoulou T. Sulfated polysaccharides increase plasma levels of SDF-1 in monkeys and mice: involvement in mobilization of stem/progenitor cells. Blood Jan. 1 2002, 99(1):44-51.
50. Sweeney E.A., Priestley G.V., Nakamoto B., Collins R.G., Beaudet A.L., Papayannopoulou T. Mobilization of stem/progenitor cells by sulfated polysaccharides does not require selectin presence. Proc Natl Acad Sci U S A Jun. 6 2000, 97(12):6544-6549.
51. Levesque J.P., Helwani F.M., Winkler I.G. The endosteal 'osteoblastic' niche and its role in hematopoietic stem cell homing and mobilization. Leukemia Dec. 2010, 24(12):1979-1992.
52. Adams G.B., Chabner K.T., Alley I.R., Olson D.P., Szczepiorkowski Z.M., Poznansky M.C., et al. Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. Nature Feb. 2 2006, 439(7076):599-603.
53. Golan K., Vagima Y., Ludin A., Itkin T., Cohen-Gur S., Kalinkovich A., et al. S1P promotes murine progenitor cell egress and mobilization via S1P1-mediated ROS signaling and SDF-1 release. Blood Mar 15 2012, 119(11):2478-2488.
54. Juarez J.G., Harun N., Thien M., Welschinger R., Baraz R., Pena A.D., et al. Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by CXCR4 antagonists in mice. Blood Jan. 19 2012, 119(3):707-716.
55. Kimura T., Boehmler A.M., Seitz G., Kuci S., Wiesner T., Brinkmann V., et al. The sphingosine 1-phosphate receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD34+ progenitor cells. Blood Jun. 15 2004, 103(12):4478-4486.
56. Ratajczak M.Z., Lee H., Wysoczynski M., Wan W., Marlicz W., Laughlin M.J., et al. Novel insight into stem cell mobilization-plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/membrane attack complex. Leukemia May 2010, 24(5):976-985.
57. Ratajczak M.Z., Kim C.H., Abdel-Latif A., Schneider G., Kucia M., Morris A.J., et al. A novel perspective on stem cell homing and mobilization: review on bioactive lipids as potent chemoattractants and cationic peptides as underappreciated modulators of responsiveness to SDF-1 gradients. Leukemia Jan. 2012, 26(1):63-72.
58. Seitz G., Boehmler A.M., Kanz L., Mohle R. The role of sphingosine 1-phosphate receptors in the trafficking of hematopoietic progenitor cells. Ann N Y Acad Sci 2005, 1044(1):84-89.
59. Malcher-Lopes R., Buzzi M. Glucocorticoid-regulated crosstalk between arachidonic acid and endocannabinoid biochemical pathways coordinates cognitive-, neuroimmune-, and energy homeostasis-related adaptations to stress. Vitam Horm 2009, 81:263-313.
60. De Petrocellis L., Cascio M.G., Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol Mar. 2004, 141(5):765-774.
61. Hoggatt J., Pelus L.M. Eicosanoid regulation of hematopoiesis and hematopoietic stem and progenitor trafficking. Leukemia Dec. 2010, 24(12):1993-2002.
62. Chevaleyre V., Takahashi K.A., Castillo P.E. Endocannabinoid-mediated synaptic plasticity in the CNS. Annu Rev Neurosci 2006, 29:37-76.
63. Jiang S., Fu Y., Avraham H.K. Regulation of hematopoietic stem cell trafficking and mobilization by the endocannabinoid system. Transfusion Nov. 2011, 51(Suppl. 4):65S-71S.
64. Jiang S., Zagozdzon R., Jorda M.A., Parmar K., Fu Y., Williams J.S., et al. Endocannabinoids are expressed in bone marrow stromal niches and play a role in interactions of hematopoietic stem and progenitor cells with the bone marrow microenvironment. J Biol Chem November 12, 2010, 285(46):35471-35478.
65. Morrison S.J., Wright D.E., Weissman I.L. Cyclophosphamide/granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization. Proc Natl Acad Sci March 4 1997, 94(5):1908-1913.
66. Levesque J.-P., Hendy J., Takamatsu Y., Simmons P.J., Bendall L.J. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003, 111(2):187-196.
67. Levesque J.-P., Hendy J., Takamatsu Y., Williams B., Winkler I.G., Simmons P.J. Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp Hematol 2002, 30(5):440-449.
68. Levesque J.-P., Takamatsu Y., Nilsson S.K., Haylock D.N., Simmons P.J. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood September 1 2001, 98(5):1289-1297.
69. Heissig B., Hattori K., Dias S., Friedrich M., Ferris B., Hackett N.R., et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell May 31 2002, 109(5):625-637.
70. Levesque J.-P., Liu F., Simmons P.J., Betsuyaku T., Senior R.M., Pham C., et al. Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood July 1 2004, 104(1):65-72.
71. Winkler I.G., Pettit A.R., Raggatt L.J., Jacobsen R.N., Forristal C.E., Barbier V., et al. Hematopoietic stem cell mobilizing agents G-CSF, cyclophosphamide or AMD3100 have distinct mechanisms of action on bone marrow HSC niches and bone formation. Leukemia Jan. 23 2012, 26(7):1594-1601.
72. Broxmeyer H.E., Hangoc G., Cooper S., Campbell T., Ito S., Mantel C. AMD3100 and CD26 modulate mobilization, engraftment, and survival of hematopoietic stem and progenitor cells mediated by the SDF-1/CXCL12-CXCR4 axis. Ann N Y Acad Sci Jun. 2007, 1106:1-19.
73. Christopherson K.W., Hangoc G., Mantel C.R., Broxmeyer H.E. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science Aug. 13 2004, 305(5686):1000-1003.
74. Christopherson K.W., Cooper S., Broxmeyer H.E. Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells. Blood Jun. 15 2003, 101(12):4680-4686.
75. Christopherson K.W., Cooper S., Hangoc G., Broxmeyer H.E. CD26 is essential for normal G-CSF-induced progenitor cell mobilization as determined by CD26-/- mice. Exp Hematol Nov. 2003, 31(11):1126-1134.
76. Paganessi L.A., Walker A.L., Tan L.L., Holmes I., Rich E., Fung H.C., et al. Effective mobilization of hematopoietic progenitor cells in G-CSF mobilization defective CD26-/- mice through AMD3100-induced disruption of the CXCL12-CXCR4 axis. Exp Hematol Mar. 2011, 39(3):384-390.
77. Bensinger W.I., Martin P.J., Storer B., Clift R., Forman S.J., Negrin R., et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med Jan. 18 2001, 344(3):175-181.
78. Blaise D., Kuentz M., Fortanier C., Bourhis J.H., Milpied N., Sutton L., et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol Feb. 2000, 18(3):537-546.
79. Champlin R.E., Schmitz N., Horowitz M.M., Chapuis B., Chopra R., Cornelissen J,J., et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood Jun. 15 2000, 95(12):3702-3709.
80. Couban S., Simpson D.R., Barnett M.J., Bredeson C., Hubesch L., Howson-Jan K., et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood Sep. 1 2002, 100(5):1525-1531.
81. Cutler C., Giri S., Jeyapalan S., Paniagua D., Viswanathan A., Antin J.H. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol Aug. 15 2001, 19(16):3685-3691.
82. Friedrichs B., Tichelli A., Bacigalupo A., Russell N.H., Ruutu T., Shapira M.Y., et al. Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol Apr. 2010, 11(4):331-338.
83. Korbling M., Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?. Blood Nov. 15 2001, 98(10):2900-2908.
84. Mohty M., Kuentz M., Michallet M., Bourhis J.H., Milpied N., Sutton L., et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood Nov. 1 2002, 100(9):3128-3134.
85. Schmitz N., Bacigalupo A., Hasenclever D., Nagler A., Gluckman E., Clark P., et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant May 1998, 21(10):995-1003.
86. Schmitz N., Beksac M., Hasenclever D., Bacigalupo A., Ruutu T., Nagler A., et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood Aug. 1 2002, 100(3):761-767.
87. Mielcarek M., Storer B., Martin P.J., Negrin R.S., Forman S.J., Flowers M.E.D., et al. Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow. Blood March 15 2012, 119(11):2675-2678.
88. Anasetti C., Logan B.R., Lee S.J., Waller E.K., Weisdorf D.J., Wingard J.R., et al. Increased incidence of chronic graft-versus-host disease (GVHD) and no survival advantage with filgrastim-mobilized peripheral blood stem cells (PBSC) compared to bone marrow (BM) transplants from unrelated donors: results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0201, a phase III, prospective, randomized trial. ASH Annu Meet Abstr November 18 2011, 118(21):1.
89. Devine S.M., Brown R.A., Mathews V., Trinkaus K., Khoury H., Adkins D., et al. Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone. Bone Marrow Transplant Sep. 2005, 36(6):531-538.
90. Lane T.A., Ho A.D., Bashey A., Peterson S., Young D., Law P. Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage- and granulocyte-colony-stimulating factors. Transfusion Jan. 1999, 39(1):39-47.
91. Lane T.A., Law P., Maruyama M., Young D., Burgess J., Mullen M., et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood Jan. 1 1995, 85(1):275-282.
92. Sohn S.K., Kim J.G., Seo K.W., Chae Y.S., Jung J.T., Suh J.S., et al. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant Jul. 2002, 30(2):81-86.
93. Sohn S.K., Kim J.G., Sung W.J., Kim D.H., Suh J.S., Lee K.S., et al. Harvesting peripheral blood stem cells from healthy donors on 4th day of cytokine mobilization. J Clin Apher 2003, 18(4):186-189.
94. Kim S.N., Moon J.H., Kim J.G., Chae Y.S., Cho Y.Y., Lee S.J., et al. Mobilization effects of G-CSF, GM-CSF, and darbepoetin-alpha for allogeneic peripheral blood stem cell transplantation. J Clin Apher 2009, 24(5):173-179.
95. Daro E., Butz E., Smith J., Teepe M., Maliszewski C.R., McKenna H.J. Comparison of the functional properties of murine dendritic cells generated in vivo with FLT3 ligand, GM-CSF and FLT3 ligand plus GM-CSF. Cytokine 2002, 17(3):119-130.
96. Vasu C., Dogan R.N., Holterman M.J., Prabhakar B.S. Selective induction of dendritic cells using granulocyte macrophage-colony stimulating factor, but not fms-like tyrosine kinase receptor 3-ligand, activates thyroglobulin-specific CD4+/CD25+ T cells and suppresses experimental autoimmune thyroiditis. J Immunol Jun. 1 2003, 170(11):5511-5522.
97. Edinger M., Hoffmann P., Ermann J., Drago K., Fathman C.G., Strober S., et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med Sep. 2003, 9(9):1144-1150.
98. Taylor P.A., Lees C.J., Blazar B.R. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood May 15 2002, 99(10):3493-3499.
99. Hashimoto S., Itoh M., Nishimura M., Asai T. Effect of filgrastim administration for steady-state mobilization of peripheral blood stem cells. Ther Apher Dec. 2002, 6(6):431-436.
100. Kroger N., Renges H., Kruger W., Gutensohn K., Loliger C., Carrero I., et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol Dec. 2000, 111(3):761-765.
101. Engelhardt M., Bertz H., Afting M., Waller C.F., Finke J. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection. J Clin Oncol Jul. 1999, 17(7):2160-2172.
102. Ings S.J., Balsa C., Leverett D., Mackinnon S., Linch D.C., Watts M.J. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol Sep. 2006, 134(5):517-525.
103. Anderlini P., Przepiorka D., Seong D., Miller P., Sundberg J., Lichtiger B., et al. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion Jul. 1996, 36(7):590-595.
104. Balaguer H., Galmes A., Ventayol G., Bargay J., Besalduch J. Splenic rupture after granulocyte-colony-stimulating factor mobilization in a peripheral blood progenitor cell donor. Transfusion Aug. 2004, 44(8):1260-1261.
105. Becker P.S., Wagle M., Matous S., Swanson R.S., Pihan G., Lowry P.A., et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant Apr. 1997, 3(1):45-49.
106. Dincer A.P., Gottschall J., Margolis D.A. Splenic rupture in a parental donor undergoing peripheral blood progenitor cell mobilization. J Pediatr Hematol Oncol Nov. 2004, 26(11):761-763.
107. Falzetti F., Aversa F., Minelli O., Tabilio A. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet Feb 13 1999, 353(9152):555.
108. Hoglund M., Smedmyr B., Bengtsson M., Totterman T.H., Cour-Chabernaud V., Yver A., et al. Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy volunteers-a comparative study. Eur J Haematol Sep. 1997, 59(3):177-183.
109. Nissen C., Carbonare V.D., Moser Y. In vitro comparison of the biological potency of glycosylated versus nonglycosylated rG-CSF. Clin Drug Investig 1994, 7(6):346-352.
110. Lefrere F., Bernard M., Audat F., Cavazzana-Calvo M., Belanger C., Hermine O., et al. Comparison of lenograstim vs filgrastim administration following chemotherapy for peripheral blood stem cell (PBSC) collection: a retrospective study of 126 patients. Leuk Lymphoma Nov. 1999, 35(5-6):501-505.
111. Carter C.R.D., Keeble J.R., Thorpe R. Human serum inactivates non-glycosylated but not glycosylated granulocyte colony stimulating factor by a protease dependent mechanism: significance of carbohydrates on the glycosylated molecule. Biologicals 2004, 32(1):37-47.
112. Nissen C. Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency. Eur J Cancer 1994, 30A(Suppl. 3):S12-S14.
113. Kroschinsky F., Holig K., Poppe-Thiede K., Zimmer K., Ordemann R., Blechschmidt M., et al. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors. Haematologica Dec. 2005, 90(12):1665-1671.
114. De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov 2003, 2(7):581-587.
115. Donzella G.A., Schols D., Lin S.W., Este J.A., Nagashima K.A., Maddon P.J., et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med Jan. 1998, 4(1):72-77.
116. Broxmeyer H.E., Orschell C.M., Clapp D.W., Hangoc G., Cooper S., Plett P.A., et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med Apr. 18 2005, 201(8):1307-1318.
117. Devine S.M., Vij R., Rettig M., Todt L., McGlauchlen K., Fisher N., et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood Aug. 15 2008, 112(4):990-998.
118. Kean L.S., Sen S., Onabajo O., Singh K., Robertson J., Stempora L., et al. Significant mobilization of both conventional and regulatory T cells with AMD3100. Blood Dec. 15 2011, 118(25):6580-6590.
119. Attal M., Harousseau J.-L., Stoppa A.-M., Sotto J-J., Fuzibet J-G., Rossi J-Fo., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996, 335(2):91-97.
120. Child J.A., Morgan G.J., Davies F.E., Owen R.G., Bell S.E., Hawkins K., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348(19):1875-1883.
121. Philip T., Armitage J.O., Spitzer G., Chauvin F., Jagannath S., Cahn J-Y., et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987, 316(24):1493-1498.
122. Rohatiner A.Z.S., Nadler L., Davies A.J., Apostolidis J., Neuberg D., Matthews J., et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol June 20 2007, 25(18):2554-2559.
123. Korbling M., Dorken B., Ho A., Pezzutto A., Hunstein W., Fliedner T. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood February 1 1986, 67(2):529-532.
124. Juttner C.A., To L.B., Ho J.Q., Bardy P.G., Dyson P.G., Haylock D.N., et al. Early lympho-hemopoietic recovery after autografting using peripheral blood stem cells in acute non-lymphoblastic leukemia. Transplant Proc Feb. 1988, 20(1):40-42.
125. Bell A.J., Figes A., Oscier D.G., Hamblin T.J. Peripheral blood stem cell autografts in the treatment of lymphoid malignancies: initial experience in three patients. Br J Haematol May 1987, 66(1):63-68.
126. Bell A.J., Oscier D.G., Figes A., Hamblin T.J. Use of circulating stem cells to accelerate myeloid recovery after autologous bone marrow transplantation. Br J Haematol Oct. 1987, 67(2):252-253.
127. Kessinger A., Armitage J.O., Landmark J.D., Smith D.M., Weisenburger D.D. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood Mar. 1988, 71(3):723-727.
128. Reiffers J., Bernard P., David B., Vezon G., Sarrat A., Marit G., et al. Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukemia. Exp Hematol May 1986, 14(4):312-315.
129. To L.B., Dyson P.G., Branford A.L., Russell J.A., Haylock D.N., Ho J.Q., et al. Peripheral blood stem cells collected in very early remission produce rapid and sustained autologous haemopoietic reconstitution in acute non-lymphoblastic leukaemia. Bone Marrow Transplant Jun. 1987, 2(1):103-108.
130. To L.B., Juttner C.A., Stomski F., Vadas M.A., Kimber R.J. Immune reconstitution following peripheral blood stem cell autografting. Bone Marrow Transplant Jun. 1987, 2(1):111-112.
131. Gianni A.M., Siena S., Bregni M., Tarella C., Stern A.C., Pileri A., et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet Sep. 9 1989, 2(8663):580-585.
132. Arora M., Burns L.J., Barker J.N., Miller J.S., Defor T.E., Olujohungbe A.B., et al. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Biol Blood Marrow Transplant Jun. 2004, 10(6):395-404.
133. Kopf B., De Giorgi U., Vertogen B., Monti G., Molinari A., Turci D., et al. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization. Bone Marrow Transplant Sep. 2006, 38(6):407-412.
134. Nowrousian M.R., Waschke S., Bojko P., Welt A., Schuett P., Ebeling P., et al. Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients. Ann Oncol 2003, 14(Suppl. 1):i29-i36.
135. Weaver C.H., Schulman K.A., Wilson-Relyea B., Birch R., West W., Buckner C.D. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. J Clin Oncol Jan. 2000, 18(1):43-53.
136. Spitzer G., Adkins D., Mathews M., Velasquez W., Bowers C., Dunphy F., et al. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy. Bone Marrow Transplant Dec. 1997, 20(11):921-930.
137. Ozcelik T., Topcuoglu P., Beksac M., Ozcan M., Arat M., Biyikli Z., et al. Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF. Bone Marrow Transplant Dec. 2009, 44(12):779-783.
138. Andre M., Baudoux E., Bron D., Canon J.L., D'Hondt V., Fassotte M.F., et al. Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion Jan. 2003, 43(1):50-57.
139. Ataergin S., Arpaci F., Turan M., Solchaga L., Cetin T., Ozturk M., et al. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation. Am J Hematol Aug. 2008, 83(8):644-648.
140. Demirer T., Ayli M., Ozcan M., Gunel N., Haznedar R., Dagli M., et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol Feb. 2002, 116(2):468-474.
141. Kim S., Kim H.J., Park J.S., Lee J., Chi H.S., Park C.J., et al. Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma. Ann Hematol Oct. 2005, 84(11):742-747.
142. Dazzi C., Cariello A., Rosti G., Argnani M., Sebastiani L., Ferrari E., et al. Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's lymphoma?. Leuk Lymphoma 2000, 39(3-4):301-310.
143. Desikan K.R., Barlogie B., Jagannath S., Vesole D.H., Siegel D., Fassas A., et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol Apr. 1998, 16(4):1547-1553.
144. Narayanasami U., Kanteti R., Morelli J., Klekar A., Al-Olama A., Keating C., et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood Oct. 1 2001, 98(7):2059-2064.
145. Anagnostopoulos A., Aleman A., Yang Y., Donato M., Weber D., Champlin R., et al. Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy. Bone Marrow Transplant Mar. 2004, 33(6):623-628.
146. Demirkazik A., Kessinger A., Armitage J.O., Bierman P.J., Lynch J., Vose J., et al. Progenitor and lymphoma cells in blood stem cell harvests: impact on survival following transplantation. Bone Marrow Transplant Jul. 2001, 28(2):207-212.
147. DiPersio J.F., Ho A.D., Hanrahan J., Hsu F.J., Fruehauf S. Relevance and clinical implications of tumor cell mobilization in the autologous transplant setting. Biol Blood Marrow Transplant 2011, 17(7):943-955.
148. Ho J., Yang L., Banihashemi B., Martin L., Halpenny M., Atkins H., et al. Contaminating tumour cells in autologous PBSC grafts do not influence survival or relapse following transplant for multiple myeloma or B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant Feb. 2009, 43(3):223-228.
149. Devine S.M., Flomenberg N., Vesole D.H., Liesveld J., Weisdorf D., Badel K., et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol Mar. 15 2004, 22(6):1095-1102.
150. Calandra G., McCarty J., McGuirk J., Tricot G., Crocker S.A., Badel K., et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant Feb. 2008, 41(4):331-338.
151. Cashen A., Lopez S., Gao F., Calandra G., MacFarland R., Badel K., et al. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant Nov. 2008, 14(11):1253-1261.
152. Flomenberg N., Comenzo R.L., Badel K., Calandra G. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation. Biol Blood Marrow Transplant May 2010, 16(5):695-700.
153. Fowler C.J., Dunn A., Hayes-Lattin B., Hansen K., Hansen L., Lanier K., et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant Jun. 2009, 43(12):909-917.
154. Stiff P., Micallef I., McCarthy P., Magalhaes-Silverman M., Weisdorf D., Territo M., et al. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant Feb. 2009, 15(2):249-256.
155. DiPersio J.F., Micallef I.N., Stiff P.J., Bolwell B.J., Maziarz R.T., Jacobsen E., et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol Oct. 1 2009, 27(28):4767-4773.
156. DiPersio J.F., Stadtmauer E.A., Nademanee A., Micallef I.N., Stiff P.J., Kaufman J.L., et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood Jun. 4 2009, 113(23):5720-5726.
157. Abhyankar S., DeJarnette S., Aljitawi O., Ganguly S., Merkel D., McGuirk J. A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transplant Apr. 2012, 47(4):483-487.
158. Costa L.J., Miller A.N., Alexander E.T., Hogan K.R., Shabbir M., Schaub C., et al. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplant 2011, 46(4):523-528.
159. Horwitz M.E., Chute J.P., Gasparetto C., Long G.D., McDonald C., Morris A., et al. Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration. Bone Marrow Transplant Nov. 14 2011.
160. Kymes S.M., Pusic I., Lambert D.L., Gregory M., Carson K.R., DiPersio J.F. Economic evaluation of plerixafor for stem cell mobilization. Am J Manag Care Jan. 2012, 18(1):33-41.
161. Brando B., Barnett D., Janossy G., Mandy F., Autran B., Rothe G., et al. Cytofluorometric methods for assessing absolute numbers of cell subsets in blood. European Working Group on Clinical Cell Analysis. Cytometry Dec. 15 2000, 42(6):327-346.
162. Siena S., Bregni M., Brando B., Belli N., Ravagnani F., Gandola L., et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood Jan. 15 1991, 77(2):400-409.
163. Chapple P., Prince H.M., Wall D., Filshie R., Haylock D., Quinn M., et al. Comparison of three methods of CD34+ cell enumeration in peripheral blood: dual-platform ISHAGE protocol versus single-platform, versus microvolume fluorimetry. Cytotherapy 2000, 2(5):371-376.
164. Gratama J.W., Sutherland D.R., Keeney M., Papa S. Flow cytometric enumeration and immunophenotyping of hematopoietic stem and progenitor cells. J Biol Regul Homeost Agents Jan.-Mar. 2001, 15(1):14-22.
165. Beguin Y., Baudoux E., Sautois B., Fraipont V., Schaaf-Lafontaine N., Pereira M., et al. Hematopoietic recovery in cancer patients after transplantation of autologous peripheral blood CD34+ cells or unmanipulated peripheral blood stem and progenitor cells. Transfusion Feb. 1998, 38(2):199-208.
166. Bender J.G., To L.B., Williams S., Schwartzberg L.S. Defining a therapeutic dose of peripheral blood stem cells. J Hematother Winter 1992, 1(4):329-341.
167. Bensinger W., Appelbaum F., Rowley S., Storb R., Sanders J., Lilleby K., et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol October 1 1995, 13(10):2547-2555.
168. Glaspy J.A., Shpall E.J., LeMaistre C.F., Briddell R.A., Menchaca D.M., Turner S.A., et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood Oct. 15 1997, 90(8):2939-2951.
169. Ketterer N., Salles G., Raba M., Espinouse D., Sonet A., Tremisi P., et al. High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood May 1 1998, 91(9):3148-3155.
170. Passos-Coelho J.L., Braine H.G., Davis J.M., Huelskamp A.M., Schepers K.G., Ohly K., et al. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. J Clin Oncol March 1, 1995, 13(3):705-714.
171. Reiffers J., Faberes C., Boiron J.M., Marit G., Foures C., Ferrer A.M., et al. Peripheral blood progenitor cell transplantation in 118 patients with hematological malignancies: analysis of factors affecting the rate of engraftment. J Hematother Fall 1994, 3(3):185-191.
172. Weaver C., Hazelton B., Birch R., Palmer P., Allen C., Schwartzberg L., et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood November 15 1995, 86(10):3961-3969.
173. Yoon D.H., Sohn B.S., Jang G., Kim E.K., Kang B.W., Kim C., et al. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma. Transfusion Sep. 2009, 49(9):1890-1900.
174. Schulman K.A., Birch R., Zhen B., Pania N., Weaver C.H. Effect of CD34+ cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. J Clin Oncol April 1, 1999, 17(4):1227.
175. Mohty M., Bilger K., Jourdan E., Kuentz M., Michallet M., Bourhis J.H., et al. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia 2003, 17(5):869-875.
176. Zaucha J.M., Gooley T., Bensinger W.I., Heimfeld S., Chauncey T.R., Zaucha R., et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood December 1 2001, 98(12):3221-3227.
177. Cashen A.F., Lazarus H.M., Devine S.M. Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF?. Bone Marrow Transplant May 2007, 39(10):577-588.
178. Gorin N.-C., Labopin M., Boiron J.-M., Theorin N., Littlewood T., Slavin S., et al. Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond-the acute leukemia working party of the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol August 20 2006, 24(24):3959-3966.
179. Pulsipher M.A., Chitphakdithai P., Logan B.R., Leitman S.F., Anderlini P., Klein J.P., et al. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood September 24 2009, 114(13):2606-2616.
180. Clark R.E., Brammer C.G. Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system. Bone Marrow Transplant Nov. 1998, 22(9):859-863.
181. Tournilhac O., Cazin B., Lepretre S., Divine M., Maloum K., Delmer A., et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood Jan. 1 2004, 103(1):363-365.
182. Kumar S., Dispenzieri A., Lacy M.Q., Hayman S.R., Buadi F.K., Gastineau D.A., et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia Sep. 2007, 21(9):2035-2042.
183. Mazumder A., Kaufman J., Niesvizky R., Lonial S., Vesole D., Jagannath S. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia Jun. 2008, 22(6):1280-1281. [author reply 1281-1282].
184. Paripati H., Stewart A.K., Cabou S., Dueck A., Zepeda V.J., Pirooz N., et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia Jun. 2008, 22(6):1282-1284.
185. Hosing C., Saliba R.M., Ahlawat S., Korbling M., Kebriaei P., Alousi A., et al. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol Jun. 2009, 84(6):335-337.
186. Kuittinen T., Nousiainen T., Halonen P., Mahlamaki E., Jantunen E. Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant May 2004, 33(9):907-912.
187. Putkonen M., Rauhala A., Pelliniemi T.-T., Remes K. Sepsis, low platelet nadir at mobilization and previous IFN use predict stem cell mobilization failure in patients with multiple myeloma. Cytotherapy 2007, 9(6):548-554.
188. Ozkurt Z.N., Yegin Z.A., Suyani E., Aki S.Z., Acar K., Yagci M., et al. Factors affecting stem cell mobilization for autologous hematopoietic stem cell transplantation. J Clin Apher 2010, 25(5):280-286.
189. Corso A., Varettoni M., Mangiacavalli S., Zappasodi P., Klersy C., Rusconi C., et al. Bone marrow CD34+ cell count is predictive for adequate peripheral progenitor cell collection. Leuk Res Feb. 2005, 29(2):159-163.
190. Fadini G.P., Miorin M., Facco M., Bonamico S., Baesso I., Grego F., et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol May 3 2005, 45(9):1449-1457.
191. Fadini G.P., Pucci L., Vanacore R., Baesso I., Penno G., Balbarini A., et al. Glucose tolerance is negatively associated with circulating progenitor cell levels. Diabetologia Oct. 2007, 50(10):2156-2163.
192. Fadini G.P., Boscaro E., de Kreutzenberg S., Agostini C., Seeger F., Dimmeler S., et al. Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. Diabetes Care May 2010, 33(5):1097-1102.
193. Ferraro F., Lymperi S., Mendez-Ferrer Sn, Saez B., Spencer J.A., Yeap B.Y., et al. Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med October 12 2011, 3(104):104ra101.
194. Facon T., Harousseau J.L., Maloisel F., Attal M., Odriozola J., Alegre A., et al. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. Blood Aug. 15 1999, 94(4):1218-1225.
195. Shpall E.J., Wheeler C.A., Turner S.A., Yanovich S., Brown R.A., Pecora A.L., et al. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood Apr. 15 1999, 93(8):2491-2501.
196. Weaver A., Chang J., Wrigley E., de Wynter E., Woll P.J., Lind M., et al. Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer. J Clin Oncol Aug. 1998, 16(8):2601-2612.
197. Dawson M.A., Schwarer A.P., Muirhead J.L., Bailey M.J., Bollard G.M., Spencer A. Successful mobilization of peripheral blood stem cells using recombinant human stem cell factor in heavily pretreated patients who have failed a previous attempt with a granulocyte colony-stimulating factor-based regimen. Bone Marrow Transplant 2005, 36(5):389-396.
198. Costa J.J., Demetri G.D., Harrist T.J., Dvorak A.M., Hayes D.F., Merica E.A., et al. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med Jun. 1 1996, 183(6):2681-2686.
199. Schmitt S., Weinhold N., Dembowsky K., Neben K., Witzens-Harig M., Braun M., et al. First results of a phase-II study with the new CXCR4 antagonist POL6326 to mobilize hematopoietic stem cells (HSC) in multiple myeloma (MM). ASH Annu Meet Abstr November 19 2010, 116(21):824.
200. Nagler A., Shimoni A., Avivi I., Rowe J.M., Beider K., Hardan I., et al. BKT140 is a novel CXCR4 antagonist with stem cell mobilization and antimyeloma effects: an open-label first human trial in patients with multiple myeloma undergoing stem cell mobilization for autologous transplantation. ASH Annu Meet Abstr November 19 2010, 116(21):2260.
201. Chung D.T., Chang L.-W., Huang Y.-H., Tsai C-Y., Hsu C-H., King C-HR., et al. TG-0054, a novel and potent stem cell mobilizer, displays excellent PK/PD and safety profile in phase I trial. ASH Annu Meet Abstr November 20, 2009, 114(22):866.
202. Huang Y.-H., Liu Y.-C., Yen C.-F., Chen H-C., Chen S-J., King C-HR., et al. Rapid mobilization of murine hematopoietic stem and progenitor cells with TG-0054, a novel CXCR4 antagonist. ASH Annu Meet Abstr November 20 2009, 114(22):3542.
203. Zohren F., Toutzaris D., Klarner V., Hartung H.-P., Kieseier B., Haas R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood April 1, 2008, 111(7):3893-3895.
204. Bonig H., Watts K.L., Chang K.-H., Kiem H.-P., Papayannopoulou T. Concurrent blockade of α4-integrin and CXCR4 in hematopoietic stem/progenitor cell mobilization. Stem Cells 2009, 27(4):836-837.
205. Ramirez P., Rettig M.P., Uy G.L., Deych E., Holt M.S., Ritchey J.K., et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood August 13 2009, 114(7):1340-1343.
206. Garrett I.R., Chen D., Gutierrez G., Zhao M., Escobedo A., Rossini G., et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003, 111(11):1771-1782.
207. Gazitt Y., Zhao X. An in vivo mouse model for testing the effect on hematopoietic stem cell mobilization of bortezomib alone and in combination with G-CSF. ASH Annu Meet Abstr November 20 2009, 114(22):2156.
208. Ward M.M., Mark T., Manco M., Stern J., O'Loughlin J., Shore T.B., et al. High-yield of CD34+ cells with bortezomib-based mobilization regimen is associated with specific genomic expression patterns, decrease in SDF-1 plasma levels and up-regulation of CXCR4 in multiple myeloma (MM) patients. Biol Blood Marrow Transplant 2011, 17(2):S179-S180.
209. Calvi L.M., Adams G.B., Weibrecht K.W., Weber J.M., Olson D.P., Knight M.C., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003, 425(6960):841-846.
210. Adams G.B., Martin R.P., Alley I.R., Chabner K.T., Cohen K.S., Calvi L.M., et al. Therapeutic targeting of a stem cell niche. Nat Biotechnol 2007, 25(2):238-243.
211. Ballen K.K., Shpall E.J., Avigan D., Yeap B.Y., Fisher D.C., McDermott K., et al. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant 2007, 13(7):838-843.
212. Dar A., Schajnovitz A., Lapid K., Kalinkovich A., Itkin T., Ludin A., et al. Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells. Leukemia 2011, 25(8):1286-1296.
213. Lucas D., Bruns I., Battista M., Mendez-Ferrer S., Magnon C., Kunisaki Y., et al. Norepinephrine reuptake inhibition promotes mobilization in mice: potential impact to rescue low stem cell yields. Blood April 26 2012, 119(17):3962-3965.